1. Home
  2. NMRA vs MTLS Comparison

NMRA vs MTLS Comparison

Compare NMRA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • MTLS
  • Stock Information
  • Founded
  • NMRA 2019
  • MTLS 1990
  • Country
  • NMRA United States
  • MTLS Belgium
  • Employees
  • NMRA N/A
  • MTLS N/A
  • Industry
  • NMRA
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • NMRA
  • MTLS Technology
  • Exchange
  • NMRA Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • NMRA 287.6M
  • MTLS N/A
  • IPO Year
  • NMRA 2023
  • MTLS 2014
  • Fundamental
  • Price
  • NMRA $0.64
  • MTLS $5.51
  • Analyst Decision
  • NMRA Buy
  • MTLS
  • Analyst Count
  • NMRA 8
  • MTLS 0
  • Target Price
  • NMRA $9.29
  • MTLS N/A
  • AVG Volume (30 Days)
  • NMRA 876.3K
  • MTLS 131.3K
  • Earning Date
  • NMRA 05-12-2025
  • MTLS 04-24-2025
  • Dividend Yield
  • NMRA N/A
  • MTLS N/A
  • EPS Growth
  • NMRA N/A
  • MTLS 43.31
  • EPS
  • NMRA N/A
  • MTLS 0.17
  • Revenue
  • NMRA N/A
  • MTLS $291,295,936.00
  • Revenue This Year
  • NMRA N/A
  • MTLS $6.55
  • Revenue Next Year
  • NMRA N/A
  • MTLS $9.21
  • P/E Ratio
  • NMRA N/A
  • MTLS $30.75
  • Revenue Growth
  • NMRA N/A
  • MTLS 6.16
  • 52 Week Low
  • NMRA $0.62
  • MTLS $3.93
  • 52 Week High
  • NMRA $17.19
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 27.87
  • MTLS 63.19
  • Support Level
  • NMRA $0.73
  • MTLS $5.21
  • Resistance Level
  • NMRA $0.72
  • MTLS $5.43
  • Average True Range (ATR)
  • NMRA 0.06
  • MTLS 0.20
  • MACD
  • NMRA 0.02
  • MTLS 0.09
  • Stochastic Oscillator
  • NMRA 4.91
  • MTLS 93.39

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: